Toward theragnostics

@article{Pne2009TowardT,
  title={Toward theragnostics},
  author={Fr{\'e}d{\'e}ric P{\`e}ne and Emilie Courtine and Alain Cariou and Jean Paul Mira},
  journal={Critical Care Medicine},
  year={2009},
  volume={37},
  pages={S50-S58}
}
Theragnostics is a treatment strategy that combines therapeutics with diagnostics. It associates both a diagnostic test that identifies patients most likely to be helped or harmed by a new medication, and targeted drug therapy based on the test results. Bioinformatics, genomics, proteomics, and functional genomics are molecular biology tools essential for the progress of molecular theragnostics. These tools generate the genetic and protein information required for the development of diagnostic… Expand
MicroRNA theragnostics for the clinical management of multiple myeloma
TLDR
The development of miRNA theragnostics should provide widely applicable tools for the targeted delivery of personalized medicines to improve the outcome of patients with multiple myeloma. Expand
Companion Diagnostics and Molecular Imaging
TLDR
The role of CDx assays, molecular imaging with its ability to image at the genetic and receptor level has made foray into the field of drug development and personalized medicine, and the upcoming concept of Theranostics is reviewed. Expand
Theranostics: A treasured tailor for tomorrow
TLDR
Theranostics is a holistic transition from trial and error medicine to predictive, preventive and personalized medicine leading to improved quality care of pharmacotherapy. Expand
Combining targeted therapies: practical issues to consider at the bench and bedside.
TLDR
Various novel trial designs are proposed that are logical for determining the efficacy of a drug or drug combination for personalized treatment and help answer questions surrounding combinatorial treatment. Expand
Personalized medicine in sepsis: the coming of age
TLDR
There is both the need to discover specific and clinically useful biomarkers in order to diagnose sepsis, define the host’s immune status, monitor treatment and define prognosis and to develop medications that would target the disease profile of each patient. Expand
La farmacogenomica en medicina
TLDR
This work carried out a systematic review about pharmacogenomic oriented to the use and clinical impact of drugs to identify molecular targets able to be intervened by drugs. Expand
Translating Biomarkers of Cholangiocarcinoma for Theranosis: A Systematic Review
TLDR
This review highlights existing validated markers of CCA that can be used for active tumor targeting for the future development of targeted theranostic delivery systems and emphasizes the relevance of bioinformatics in aiding the search for validated biomarkers that could be repurposed for theranosis. Expand
Using a theragnostic approach in juvenile idiopathic arthritis
TLDR
This review will serve to educate the reader on recent success of targeted therapy in systemic juvenile idiopathic arthritis and how the field is impacted and the platforms that may help revolutionize the discovery of the elusive target. Expand
Recent advances in nanoscale materials for antibody-based cancer theranostics.
TLDR
This review comprehensively discusses and evaluates recent advances in the application of nanomaterial-antibody bioconjugates for cancer theranostics for the further advancement in the control of diverse cancerous diseases. Expand
Neurotheranostics as personalized medicines.
TLDR
An extensive body of knowledge of the natural history, epidemiology, pathogenesis and therapeutics of neurologic disease is reviewed with an eye on how, when and under what circumstances neurotheranostics will soon be used as personalized medicines for a broad range of neurodegenerative, neuroinflammatory and neuroinfectious diseases. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 47 REFERENCES
TPMT, UGT1A1 and DPYD: genotyping to ensure safer cancer therapy?
TLDR
Reviewing the gene-drug-phenotype relationships of 6-MP, irinotecan and 5-fluorouracil reveals properties of these relationships that lead to a clinically useful pharmacogenetic test. Expand
Biomarker Development, Commercialization, and Regulation: Individualization of Medicine Lost in Translation
TLDR
The paucity of validated highly complex biomarkers has engendered previously unrecognized issues surrounding their approval and marketing by regulatory agencies, and generated new partnerships among federal agencies, academia, and the pharmaceutical and biotechnology industries. Expand
Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin
TLDR
Although the routine use of warfarin genotyping is not endorsed by this work group at this time, in certain situations, CYP2C9 and VKORC1 testing may be useful, and warranted, in determining the cause of unusual therapeutic responses to warFarin therapy. Expand
Moving towards individualized medicine with pharmacogenomics
TLDR
The intersection of genomics and medicine has the potential to yield a new set of molecular diagnostic tools that can be used to individualize and optimize drug therapy. Expand
Microarrays to identify new therapeutic strategies for cancer.
TLDR
This chapter will provide examples where microarray analysis has been used in an attempt to either direct the use of current therapies or identify new potential therapeutic avenues. Expand
Treatment with CCR5 antagonists: which patient may have a benefit?
TLDR
MVR is not licensed for treatment naive patients but it has a high potential for further development in this patient group and shows better immunological reconstitution than efavirenz, and will be of benefit for patients in various treatment situations and regions. Expand
Positron emission tomography imaging as a cancer biomarker
TLDR
In this review, cancer biomarker development, opportunities for PET to elucidate tumor biology and the potential role of PET in clinical research and practice are discussed. Expand
Functional PET imaging in cancer drug development.
TLDR
Summative readouts by PET, such as drug-induced changes in tumor glucose metabolism, tumor cell proliferation and tumor perfusion and, similarly, measures of specific changes will demonstrate whether drugs are having their intended biological effects. Expand
Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting.
TLDR
The Molecular Assays in NSCLC Working Group was convened to evaluate the available molecular assays for use in the clinical trial setting and provide recommendations for application and interpretation of these tests for future clinical trials. Expand
Drug hypersensitivity in HIV
TLDR
The potential for widespread implementation of HLA-B*5701 screening for abacavir hypersensitivity will set an important precedent for bringing individualized medicine to the clinic and the use of genetic testing to improve drug safety. Expand
...
1
2
3
4
5
...